A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?
about
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.Bortezomib in multiple myeloma: systematic review and clinical considerations.Late recurrence of light chain deposition disease after kidney transplantation treated with bortezomib: a case reportSuccessful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report.Bortezomib for the treatment of previously untreated multiple myeloma.
P2860
A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 July 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A systematic review on the use ...... hat is the published evidence?
@en
A systematic review on the use ...... hat is the published evidence?
@nl
type
label
A systematic review on the use ...... hat is the published evidence?
@en
A systematic review on the use ...... hat is the published evidence?
@nl
prefLabel
A systematic review on the use ...... hat is the published evidence?
@en
A systematic review on the use ...... hat is the published evidence?
@nl
P2860
P356
P1433
P1476
A systematic review on the use ...... hat is the published evidence?
@en
P2093
Eugenio Piro
Stefano Molica
P2860
P304
P356
10.1159/000328417
P577
2011-07-21T00:00:00Z